As ITGB2 was upregulated in human ectopic endometrial tissues (Figure 5B), we hypothesized that Lifitegrast, an antagonist of lymphocyte function‐associated antigen 1 (LFA‐1) that is approved for dry eye disease, may be a candidate intervention for treating endometriosis. The gene discussed is ITGB2; the disease is endometriosis.